2020 ASCO Virtual Direct™ Highlights

 

Hematologic Oncology
08:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Brentuximab Vedotin vs. Pembrolizumab - Which Single Agent Should You Pick First for R/R cHL?

FEATURING Neha Mehta-Shah
  • 397 views
  • July 22, 2020
  • 4
07:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Should You Abandon ASCT in Patients With PR Combination Chemotherapy in DLBCL?

FEATURING Neha Mehta-Shah
  • 284 views
  • July 22, 2020
  • 1
08:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update: Zanubrutinib vs. Ibrutinib - Are Newer Generation BTK Inhibitors Better for Waldenstrom’s Macroglobulinemia? Can Venetoclax Be Added to DA-R-EPOCH in DLBCL and Richter’s?

FEATURING Neha Mehta-Shah
  • 26 views
  • July 22, 2020
04:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Is Anti-CD47 Antibody Magrolimab + Azacitidine Effective and Well Tolerated in TP53-mutant AML?

FEATURING Ravi Vij
  • 23 views
  • July 22, 2020
07:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Are Ivosidenib and Enasidenib Good Options to Be Added to the Backbone of HMAs?

FEATURING Ravi Vij
  • 115 views
  • July 22, 2020
  • 1
19:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Diagnosed Disease, Weekly Selinexor Combo vs. Vd After Prior Therapy, Safety and Tolerability of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R Disease

FEATURING Ravi Vij
  • 344 views
  • July 22, 2020
  • 2